Indivior (NASDAQ:INDV) Upgraded to Strong-Buy at Zacks Research

Indivior (NASDAQ:INDV) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

INDV has been the topic of several other research reports. Northland Securities set a $40.00 price target on Indivior in a research note on Friday. HC Wainwright increased their target price on shares of Indivior from $28.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Craig Hallum restated a “buy” rating and set a $41.00 price target on shares of Indivior in a research report on Friday. Jefferies Financial Group began coverage on Indivior in a research report on Tuesday, July 22nd. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Indivior in a research report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Indivior has a consensus rating of “Buy” and a consensus price target of $32.17.

Indivior Trading Up 2.6%

INDV opened at $32.00 on Monday. Indivior has a 1 year low of $7.62 and a 1 year high of $32.14. The stock’s 50 day simple moving average is $24.53 and its 200-day simple moving average is $18.58. The stock has a market cap of $4.41 billion, a PE ratio of 51.61 and a beta of 0.68.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.34. The firm had revenue of $314.00 million for the quarter, compared to the consensus estimate of $257.66 million. Indivior had a net margin of 6.65% and a negative return on equity of 86.28%. Indivior has set its FY 2025 guidance at EPS. Equities analysts forecast that Indivior will post 1.22 earnings per share for the current fiscal year.

Institutional Trading of Indivior

Institutional investors and hedge funds have recently modified their holdings of the stock. CWM LLC acquired a new position in Indivior during the third quarter valued at approximately $25,000. Raymond James Financial Inc. acquired a new stake in Indivior during the 2nd quarter worth $26,000. Blue Trust Inc. acquired a new stake in Indivior during the 3rd quarter worth $99,000. Amalgamated Bank acquired a new stake in Indivior during the 2nd quarter worth $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Indivior by 16.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock worth $71,000 after buying an additional 666 shares during the period. 60.33% of the stock is owned by institutional investors.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.